AI Summary Imfinzi (durvalumab) is a PD-L1 inhibitor immunotherapy used alone or with Imjudo for unresectable hepatocellular carcinoma.
Medically reviewed.
Imfinzi (durvalumab) is a prescription immunotherapy used to treat several cancers, including unresectable hepatocellular carcinoma (HCC). It is a PD-L1 inhibitor, a medicine that boosts the immune system's activity against cancer. Imfinzi may be used alone or with Imjudo (tremelimumab) for advanced liver cancer. Treatment decisions should always be individualized and guided by a healthcare professional.
This page covers Imfinzi's role in liver cancer care: how it works, who may be eligible, how it is given, benefits, side effects, and monitoring. You can also connect with a liver specialist near you for personalized guidance on whether Imfinzi fits your care plan.
Liver Health AI Assistant
Ask Aimy
Aimy answers from LiverDirectory’s reviewed health information — helping patients make sense of liver-health terms, prepare for specialist visits, and explore what to look up next.
ABOUT IMFINZI TREATMENT
Imfinzi is a prescription medicine that contains durvalumab. It belongs to a class of medications called PD-L1 inhibitors, a type of immunotherapy. Immunotherapy helps the body's immune system recognize and attack cancer cells.
Imfinzi is used to treat several cancers. In liver cancer, it is used for unresectable hepatocellular carcinoma (HCC). "Unresectable" means the cancer cannot be removed with surgery.
Imfinzi may be used alone or together with Imjudo (tremelimumab) for advanced liver cancer. It is a systemic treatment, which means it treats cancer throughout the body.
A healthcare professional prepares and gives Imfinzi. Your care team also checks your response to treatment regularly, for example with Liver Function Tests (LFTs).
WHO IMFINZI MAY BE SUITABLE FOR
Your healthcare provider may prescribe Imfinzi if you have unresectable hepatocellular carcinoma and are a candidate for immunotherapy. It may be considered when surgery or local therapies alone cannot treat your cancer. It may also be considered when you may benefit from combination immunotherapy with Imjudo.
Because every patient's health profile is different, there is no one-size-fits-all answer to who should take Imfinzi. Treatment decisions are individualized and should be made by a qualified healthcare professional after a full assessment of your liver cancer, your medical history, and your treatment goals.
ELIGIBILITY OVERVIEW
Imfinzi may be considered for adults with the following conditions or treatment goals:
Before recommending Imfinzi, your healthcare provider considers several questions to decide whether it is an appropriate option, including:
HOW IMFINZI CAN HELP
Cancer cells can use an immune checkpoint pathway called PD-L1 to avoid attack by the immune system. Imfinzi blocks this pathway. This restores the immune system's ability to recognize cancer cells and enhances T-cell activity against tumors.
As a result, Imfinzi helps slow tumor progression. Some people have durable responses, which means long-lasting tumor control.
Imfinzi can be used alone. It can also be combined with Imjudo, which blocks a different checkpoint pathway called CTLA-4 and works together with Imfinzi to strengthen the immune response. Your care team tracks how you respond with regular monitoring, such as Liver Function Tests (LFTs).
LIVER CANCER CARE
Imfinzi is used for unresectable hepatocellular carcinoma, which means surgery cannot remove the cancer. Your healthcare provider may consider it when you are a candidate for immunotherapy and surgery or local therapies alone cannot treat your cancer.
By strengthening the immune response against the tumor, Imfinzi helps slow the progression of unresectable HCC. The goal is to keep the cancer from advancing for as long as possible.
Some people have durable responses, which means long-lasting tumor control. How long a response lasts varies widely, from several months to multiple years in people who respond.
Your care team regularly checks how the cancer is responding to treatment. Imfinzi continues until the disease progresses, side effects become unacceptable, or your care team decides to stop.
Imfinzi is an immunotherapy that helps your immune system find and attack liver cancer cells. It should only be started and monitored under the guidance of a qualified healthcare professional.
TREATMENT PROCESS
A healthcare professional prepares and gives Imfinzi. You do not prepare it yourself.
For unresectable hepatocellular carcinoma, Imfinzi is commonly given as 1,500 mg by vein (intravenously) every 4 weeks. Your healthcare provider determines the right dose and schedule for you.
When Imfinzi is used with Imjudo (tremelimumab-actl), the typical regimen is a single 300 mg dose of Imjudo plus 1,500 mg of Imfinzi on Day 1. After that, Imfinzi 1,500 mg continues every 4 weeks. On the same day, Imjudo is given before Imfinzi.
Imfinzi is given as an intravenous (IV) infusion over about 60 minutes, following prescribing guidelines. It is not a pill or an injection you give yourself.
Imfinzi is used as long-term, ongoing therapy in advanced hepatocellular carcinoma. Treatment continues until the disease progresses, side effects become unacceptable, or your care team decides to stop. Duration varies widely with your response, from several months to multiple years in people who respond.
Healthcare professionals store and handle Imfinzi.
Your care team regularly monitors your response to treatment and watches for immune-related side effects. Report symptoms such as cough, shortness of breath, severe fatigue, jaundice, or persistent diarrhea right away, because they may signal immune-related inflammation.
BENEFITS AND SAFETY
Imfinzi (durvalumab) may help people with unresectable hepatocellular carcinoma by activating the immune system against cancer. It treats cancer throughout the body, and some people have long-lasting tumor control. The extent of these benefits varies from person to person. Imfinzi can be used alone or combined with Imjudo for advanced liver cancer, and it works within a broader care plan that includes regular monitoring.
As with any medication, Imfinzi may cause side effects. The most common are fatigue, rash or itching, diarrhea, and decreased appetite. Imfinzi can also cause immune-related inflammation in organs such as the liver, lungs, or thyroid. Your healthcare provider will monitor you throughout treatment and decide whether Imfinzi remains a suitable option for you.
BENEFITS
Imfinzi is an immunotherapy that activates the immune system against cancer cells. Instead of attacking the tumor directly, it helps your own defenses recognize and respond to it.
Imfinzi can be used with Imjudo in advanced hepatocellular carcinoma. Your healthcare provider decides whether Imfinzi alone or the combination is the better fit for you.
Imfinzi is a systemic treatment, which means it treats cancer throughout the body rather than in one spot.
Imfinzi is given by IV infusion over about 60 minutes every 4 weeks, so you do not need to manage doses at home. Your care team prepares, stores, and handles the medicine.
Tell your healthcare provider right away about cough, shortness of breath, severe fatigue, jaundice, or persistent diarrhea. Your provider will discuss the potential benefits and risks before treatment and monitor you throughout.
SUPPORTING YOUR CARE
Daily habits can support you during Imfinzi treatment. Maintaining nutrition and hydration and keeping your scheduled infusions are important.
Report symptoms such as cough, shortness of breath, severe fatigue, jaundice, or persistent diarrhea promptly. They may indicate immune-related inflammation.
Areas that may support treatment:
common questions
A healthcare professional gives Imfinzi by intravenous (IV) infusion over about 60 minutes. For unresectable hepatocellular carcinoma, it is commonly given as 1,500 mg every 4 weeks. You do not prepare or give it yourself. Your healthcare provider determines the dose and schedule that are right for you, so ask your care team what to expect at each visit and how to plan around infusion days.
Imfinzi may be an option if you have unresectable hepatocellular carcinoma and are a candidate for immunotherapy. Your healthcare provider may consider it when surgery or local therapies alone cannot treat your cancer, or when you may benefit from combination immunotherapy with Imjudo. Eligibility depends on your liver cancer, medical history, and treatment goals, so a qualified healthcare professional needs to make this decision with you after a full assessment.
Yes. Imfinzi may be used alone or with Imjudo (tremelimumab) for advanced liver cancer. In the typical combination regimen, you receive a single 300 mg dose of Imjudo plus 1,500 mg of Imfinzi on Day 1. Imfinzi 1,500 mg then continues every 4 weeks. Your healthcare provider decides whether Imfinzi alone or the combination fits your situation, so discuss both options with your care team.
The most common side effects of Imfinzi are fatigue, decreased appetite, rash or itching, and diarrhea. Imfinzi can also cause immune-related inflammation in organs such as the liver, lungs, or thyroid. Tell your healthcare provider right away about cough, shortness of breath, severe fatigue, jaundice, or persistent diarrhea. Your care team monitors you throughout treatment and can explain the benefits and risks for you.
Imfinzi is used as long-term, ongoing therapy in advanced hepatocellular carcinoma. Treatment continues until the disease progresses, side effects become unacceptable, or your care team decides to stop. Your response is checked with regular monitoring. Do not stop treatment on your own. Talk with your healthcare provider about how long you can expect to be treated and what would lead to a change in your plan.
Imfinzi is an immunotherapy that helps slow tumor progression in unresectable hepatocellular carcinoma, and some people have durable responses, meaning long-lasting tumor control. It is not a guaranteed cure, and results vary from person to person. Imfinzi helps your immune system recognize and attack cancer cells by blocking the PD-L1 pathway. Ask your healthcare provider what outcome is realistic for you.
Medical disclaimer: LiverDirectory provides educational information and a directory of providers. It does not provide medical advice, diagnosis, or treatment. Always consult a licensed physician regarding any medical condition.
